Pharmacoepidemiology of botulinum toxin in the complex therapy of post-stroke spasticity in the Russian Federation. The survey data of neurologists
Abstract
A pharmacoepidemiology study was performed of the use of botulinum toxin type A drugs (BTA) in the combined therapy of post-stroke spasticity in Russian Federation. Experts survey was the major method used and followed by application of the Delphi method. Questionnaire consisted of 30 questions. 12 completed questionnaires from 12 cities of Russia were analyzed as a result. Practicing neurologist participated in the survey who had experience of BTA use in combined treatment of post-stroke spasticity. Several indicators were identifi ed that represent signifi cant interest for their subsequent use, in particular, during the pharmacoeconomic studies, scientifi c analysis of outcomes with Markov modelling use, development of mathematical models.
About the Authors
Kolbin A. S.
The first St. Petersburg State Medical University named after acad. IP Pavlova;
Saint Petersburg State University
Russian Federation
Russian Federation
I. A. Vilum
First Pavlov State Medical University of St. Peterburg; National Medical and Surgical Center of the N.I. Pirogov
Russian Federation
Russian Federation
References
1. Протокол ведения больных «Инсульт». Нормативный документ. Министерство здравоохранения и социального развития РФ. 2006.
2. Суслина З.С., Танашян М.М., Ионова В.Г. Ишемический инсульт: кровь, сосудистая стенка, антитромботическая терапия. М.: Медкнига, 2005. — 248 с.
3. Кадыков А.С., Черникова Л.А., Шахпаронова Н.В. Реабилитация неврологических больных. М.: МЕДпресс-информ, 2009. — 560 с.
4. Wissel J., Manack A., Brainin M. Toward an epidemiology of poststroke spasticity. Neurology 2013; 80: S13 -9.
5. Ковальчук В.В., Скоромец A.A. Воздействие лечебной физической культуры на восстановление функций у больных после инсульта. // Вопросы курортологии физиотерапии и лечебной физкультуры. 2007. — №4. -С.26 — 28.
6. Епифанов В.А. Реабилитация больных, перенесших инсульт. -Москва: Медпресс информ, 2006. — 5 с.
7. Орлова О.Р. Применение ботокса (токсина ботулизма типа А) в клинической практике: руководство для врачей. Под ред. О. Р. Орловой, Н. Н. Яхно. М.: Каталог, 2001. — 208 с.
8. Хатькова С.Е. Использование ксеомина при лечении постинсультной спастичности. // Журнал неврологии и психиатрии им. С. С. Корсакова. 2010. — № 8. — С. 62—63.
9. Brin M. The spasticity Study Group. Dosing, administration and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. // Muscle and Nerve. 1997;20:208—220.
10. Kong K-H., Neo J-J., Chua K.S. A randomized controlled study of botulinum toxin A in the treatment of hemiplegic shoulder pain associated with spasticity. // Clinical Rehabilitation. 2007;21:28 — 35.
11. Pandyan A.D., Gregoric M., Barnes M.P., et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. // Disability Rehabilitation. 2005;27:2-6.
12. Cтрачунский Л.С., Козлов С.Н., Рачина С.А. Фармакоэпидемиология: основные понятия и практическое применение. // Клиническая фармако- логия и терапия. — 2001.- Т. 4, № 10. — С. 24-29.
13. Wilson-Davis K. Study design and the use of statistics in drug use research. In: McGavock H., editor. Handbook of Drug Use Research Methodology. 1st ed. Newcastle: The United Kingdom Drug Utilization Research Group; 2000. p. 36-55.
14. Хвещук П.Ф. Формуляр лекарственных средств: методология разработки / П.Ф. Хвещук, А.В. Рудакова. — СПб.: ВМедА, 2002. — 183 с.
15. Lundstrom E., et al. Prevalence of disabling spasticity 1 year after first-ever stroke. // European Journal of Neurology. 2008;15(6):533—539.
16. Francisco G.E., McGuire J.R. Poststroke Spasticity Management. American Heart Association. 2012; http://stroke.ahajournals.org/content/43/11/3132.
17. Hesse S., Werner C. Poststroke Motor Dysfunction and Spasticity Novel Pharmacological and Physical Treatment Strategies. // CNS Drugs 2003; 17(15):1093-1107.
18. Marciniak K. Poststroke Hypertonicity: Upper Limb Assessment and Treatment. // Top Stroke Rehabil 2011;18(3):179—194.
19. Белова А.Н., Прокопенко С.В. Нейрореабилитация. 3-е изд., перераб. и доп. М.: Антидор. 2010. 1288 с.
20. Bakheit A.M., Fedorova N.V., Skoromets A.A. The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles. // J. Neurol. Neurosurg. Psychiatry. 2004;75:1558—1561.
21. Davis E., Barnes M. The use of botulinum toxin in spasticiny. In: Upper motor neuron syndrome and spasticity. Cambridge University Press. 2001:206—222.
Review
For citations:
S. K.A., Vilum I.A. Pharmacoepidemiology of botulinum toxin in the complex therapy of post-stroke spasticity in the Russian Federation. The survey data of neurologists. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2014;(3):18-23. (In Russ.)
Views:
1503
Email this article 